Plasma protein profiling reveals candidate biomarkers for multiple sclerosis treatmentShow others and affiliations
2019 (English)In: PLOS ONE, E-ISSN 1932-6203, Vol. 14, no 5, article id e0217208Article in journal (Refereed) Published
Abstract [en]
Multiple sclerosis (MS) treatment options have improved significantly over the past decades, but the consequences of MS can still be devastating and the needs for monitoring treatment surveillance are considerable. In the current study we used affinity proteomics technology to identify potential biomarkers which could ultimately be used to as facilitate treatment decisions. We profiled the intra-individual changes in the levels of 59 target proteins using an antibody suspension bead array in serial plasma samples from 44 MS patients during treatment with natalizumab followed by fingolimod. Nine proteins showed decreasing plasma levels during natalizumab treatment, with PEBP1 and RTN3 displaying the most significant changes. Protein levels remained stable during fingolimod treatment for both proteins. The decreasing PEBP1 levels during natalizumab treatment could be validated using ELISA and replicated in an independent cohort. These results support the use of this technology as a high throughput method of identifying potentially useful biomarkers of MS treatment.
Place, publisher, year, edition, pages
PUBLIC LIBRARY SCIENCE , 2019. Vol. 14, no 5, article id e0217208
National Category
Clinical Laboratory Medicine
Identifiers
URN: urn:nbn:se:kth:diva-254015DOI: 10.1371/journal.pone.0217208ISI: 000469323000044PubMedID: 31141529Scopus ID: 2-s2.0-85066453037OAI: oai:DiVA.org:kth-254015DiVA, id: diva2:1342851
Note
QC 20190814
2019-08-142019-08-142024-03-18Bibliographically approved